Breaking Covid-19 news from $HALB!!! December
Post# of 40212
![](/assets/46931549/no_avatar_available_thumb.jpg)
December 23, 2020 / Halberd Corp. (OTC PINK:HALB) research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd's initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only the SARS-CoV-2 antigen) as well as a potential "cocktail mix" of both antibodies acting in concert.
#HALB #COVID19
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)